or Try an Advanced Search...

    Technical Analysis for PBLA - Panbela Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.36 -16.28% -0.07
    PBLA closed up 5.13 percent on Tuesday, May 28, 2024, on 11 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical PBLA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish -16.28%
    New Uptrend Bullish -16.28%
    Outside Day Range Expansion -16.28%
    Wide Bands Range Expansion -16.28%
    Gapped Down Weakness -16.28%
    NR7 Range Contraction -11.98%
    Narrow Range Bar Range Contraction -11.98%
    Wide Bands Range Expansion -11.98%
    20 DMA Resistance Bearish -12.24%
    Earnings Movers Other -12.24%
    Older End-of-Day Signals for PBLA ...

       Recent Intraday Alerts

    Alert Time
    Gap Down Partially Closed about 10 hours ago
    Gapped Down (Partial) about 10 hours ago
    Down 5% about 10 hours ago
    Down 3% about 10 hours ago
    Fell Below Lower Bollinger Band about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    PBLA Chart by TradingView
    Basic chart:

    Profile

    Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Pancreatic Cancer Carcinoma Gastrointestinal Cancer Mm 151

    Is PBLA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
    Jun 10 Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
    May 15 Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
    May 15 Panbela Therapeutics GAAP EPS of -$2.28
    May 15 Panbela Provides Business Update and Reports Q1 2024 Financial Results
    May 6 Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
    May 1 Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
    Apr 30 Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
    Apr 22 Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial
    Apr 22 Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
    See more PBLA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 246.0
    52 Week Low 0.35
    Average Volume 158,416
    200-Day Moving Average 13.63
    50-Day Moving Average 0.64
    20-Day Moving Average 0.46
    10-Day Moving Average 0.42
    Average True Range 0.10
    RSI (14) 37.50
    ADX 29.39
    +DI 17.22
    -DI 15.80
    Chandelier Exit (Long, 3 ATRs) 0.33
    Chandelier Exit (Short, 3 ATRs) 0.65
    Upper Bollinger Bands 0.58
    Lower Bollinger Band 0.34
    Percent B (%b) 0.37
    BandWidth 52.47
    MACD Line -0.11
    MACD Signal Line -0.14
    MACD Histogram 0.0295
    Fundamentals Value
    Market Cap 1.5 Million
    Num Shares 3.48 Million
    EPS -157.02
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 3.22
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.61
    Resistance 3 (R3) 0.61 0.55 0.58
    Resistance 2 (R2) 0.55 0.50 0.55 0.57
    Resistance 1 (R1) 0.49 0.47 0.52 0.49 0.56
    Pivot Point 0.42 0.42 0.44 0.43 0.42
    Support 1 (S1) 0.37 0.38 0.40 0.37 0.30
    Support 2 (S2) 0.30 0.35 0.30 0.29
    Support 3 (S3) 0.24 0.30 0.28
    Support 4 (S4) 0.25